Literature DB >> 29444977

Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence.

Giovanna Cutrona1, Claudio Tripodo2, Serena Matis3, Anna Grazia Recchia4,5, Carlotta Massucco3, Marina Fabbi6, Monica Colombo3, Laura Emionite7, Sabina Sangaletti8, Alessandro Gulino2, Daniele Reverberi3, Rosanna Massara3, Simona Boccardo9, Daniela de Totero3, Sandra Salvi9, Michele Cilli7, Mariavaleria Pellicanò4,5, Martina Manzoni10,11, Sonia Fabris11, Irma Airoldi12, Francesca Valdora3,13, Silvano Ferrini6, Massimo Gentile4,5, Ernesto Vigna4,5, Sabrina Bossio5, Laura De Stefano5, Angela Palummo5, Giovanni Iaquinta5, Martina Cardillo13, Simonetta Zupo14, Giannamaria Cerruti14, Adalberto Ibatici15, Antonino Neri10,11, Franco Fais3,13, Manlio Ferrarini16, Fortunato Morabito4,5.   

Abstract

Although the progression of chronic lymphocytic leukemia (CLL) requires the cooperation of the microenvironment, the exact cellular and molecular mechanisms involved are still unclear. We investigated the interleukin (IL)-23 receptor (IL-23R)/IL-23 axis and found that circulating cells from early-stage CLL patients with shorter time-to-treatment, but not of those with a more benign course, expressed a defective form of the IL-23R complex lacking the IL-12Rβ1 chain. However, cells from both patient groups expressed the complete IL-23R complex in tissue infiltrates and could be induced to express the IL-12Rβ1 chain when cocultured with activated T cells or CD40L+ cells. CLL cells activated in vitro in this context produced IL-23, a finding that, together with the presence of IL-23 in CLL lymphoid tissues, suggests the existence of an autocrine/paracrine loop inducing CLL cell proliferation. Interference with the IL-23R/IL-23 axis using an anti-IL-23p19 antibody proved effective in controlling disease onset and expansion in xenografted mice, suggesting potential therapeutic strategies.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29444977     DOI: 10.1126/scitranslmed.aal1571

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  4 in total

1.  A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells.

Authors:  Elena Gugiatti; Claudya Tenca; Silvia Ravera; Marina Fabbi; Fabio Ghiotto; Andrea N Mazzarello; Davide Bagnara; Daniele Reverberi; Daniela Zarcone; Giovanna Cutrona; Adalberto Ibatici; Ermanno Ciccone; Zbigniew Darzynkiewicz; Franco Fais; Silvia Bruno
Journal:  Haematologica       Date:  2018-06-21       Impact factor: 9.941

2.  LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells.

Authors:  Serena Matis; Martina Rossi; Lorenzo Brondolo; Martina Cardillo; Daniele Reverberi; Rosanna Massara; Monica Colombo; Adalberto Ibatici; Emanuele Angelucci; Tiziana Vaisitti; Silvia Bruno; Sonia Fabris; Antonino Neri; Massimo Gentile; Fortunato Morabito; Giovanna Cutrona; Paola Briata; Roberto Gherzi; Franco Fais
Journal:  Hematol Oncol       Date:  2021-10-28       Impact factor: 4.850

Review 3.  Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

Authors:  Paola Monti; Paola Menichini; Andrea Speciale; Giovanna Cutrona; Franco Fais; Elisa Taiana; Antonino Neri; Riccardo Bomben; Massimo Gentile; Valter Gattei; Manlio Ferrarini; Fortunato Morabito; Gilberto Fronza
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

4.  IL-17 and IL-23 levels in patients with early-stage chronic lymphocytic leukemia.

Authors:  Mehmet Bankir; Didar Yanardag Acik
Journal:  North Clin Istanb       Date:  2020-11-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.